VOGX
- AccessWire
Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Advances PBH Development Program Following August 2026 Initial Public OfferingStrengthens Balance Sheet with $82.1 Million in Total Cash, Cash Equivalents, and Marketable Securities RALEIGH, NC / ACCESS Newswire / ...
- AccessWire
Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia
Randomized, double-blind, placebo-controlled trial will evaluate two doses of the first-in-class, minimally absorbed SGLT1 inhibitor in patients with recurrent hypoglycemia following bariatric surgery RALEIGH, NC ...
- AccessWire
Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer
Thirty-year biopharmaceutical commercial leader transitions from the Board of Directors to Chief Commercial OfficerAppointment strengthens corporate strategy, business development and commercial readiness as the Company ...
- AccessWire
Vogenx Appoints Ken Toombs to Board of Directors
Former Chief Executive Officer of PA Consulting brings three decades of global professional services and life sciences leadership experienceAppointment broadens independent oversight as the Company scales operations ...
- Analyst Upgrades
WBB Securities Initiates Coverage On Vogenx with Speculative Buy Rating, Announces Price Target of $42
WBB Securities analyst Steve Brozak initiates coverage on Vogenx with a Speculative Buy rating and announces Price Target of $42. ...
- Analyst Upgrades
Jones Trading Initiates Coverage On Vogenx with Buy Rating, Announces Price Target of $55
Jones Trading analyst Catherine Novack initiates coverage on Vogenx with a Buy rating and announces Price Target of $55. ...
- PR Newswire
Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering
JonesTrading Institutional Services LLC ("Jones") today announced that it served as sole book-running manager for the $81.3 million initial public... ...
- AccessWire
Vogenx Announces Closing of Initial Public Offering
RALEIGH, NC / ACCESS Newswire / August 13, 2026 / Vogenx, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the ...
- AccessWire
Vogenx Announces Pricing of Initial Public Offering
RALEIGH, NC / ACCESS Newswire / August 11, 2026 / Vogenx, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the ...